P-21(Shifa Biomedical)

N/A

Report date: 2024/12/18 13:39:48
NME

Base Information

Drug NameP-21(Shifa Biomedical)
Drug Alias NameP-21
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionLDL receptor antagonistsProprotein convertase subtilisin kexin type 9 inhibitors
TargetsLDL receptorProprotein convertase subtilisin kexin type 9
Therapy Area/IndicationsDyslipidemias
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesShifa Biomedical Corp
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesN/A
Active IndicationsDyslipidemias
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A